Medical Devices India

India Neuromodulation for Depression Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

India Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $26.6 Mn Placeholder estimate
Estimate 2025 $30.1 Mn 1.9% of the global market
Projected 2034 $91.0 Mn 202.8% Adds $61.0 Mn over 9 forecast years
CAGR 2025–2034 13.1% Faster than 61% of 173 Medical Devices markets here
Key players 5
  • India is 1.91% of the global market.
  • In APAC, the largest is China at $119.2 Mn.
  • Fastest growing: India (this report) at 13.1% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$61.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $26.6 Mn — —
2025 (base) $30.1 Mn +$3.5 Mn —
2026 (forecast) $34.0 Mn +$3.9 Mn +13.1%
2027 (forecast) $38.5 Mn +$4.5 Mn +27.9%
2028 (forecast) $43.5 Mn +$5.0 Mn +44.7%
2029 (forecast) $49.2 Mn +$5.7 Mn +63.6%
2030 (forecast) $55.6 Mn +$6.4 Mn +85.1%
2031 (forecast) $62.9 Mn +$7.3 Mn +109.3%
2032 (forecast) $71.2 Mn +$8.2 Mn +136.7%
2033 (forecast) $80.5 Mn +$9.3 Mn +167.7%
2034 (forecast) $91.0 Mn +$10.5 Mn +202.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.57 Bn
  2. North America $807.4 Mn
  3. US $560.5 Mn
  4. Europe $298.1 Mn
  5. APAC $303.5 Mn
  6. China $119.2 Mn
  7. Canada $113.0 Mn
  8. Japan $104.5 Mn
  9. Latin America $73.3 Mn
  10. Middle East $62.8 Mn
  11. Germany $49.4 Mn
  12. UK $45.0 Mn
  13. France $36.7 Mn
  14. Brazil $35.9 Mn
  15. Italy $33.2 Mn
  16. Spain $32.4 Mn
  17. India (this report) $30.1 Mn
  18. Ecuador $28.2 Mn
  19. Saudi Arabia $26.3 Mn
  20. Africa $25.6 Mn
  21. Mexico $23.9 Mn
  22. Australia $17.3 Mn
  23. New Zealand $15.6 Mn
  24. Russia $15.8 Mn
  25. South Africa $9.7 Mn
  26. UAE $8.0 Mn
  27. Egypt $4.5 Mn
  28. Philippines $3.4 Mn
  29. Hong Kong $2.6 Mn
  30. Malaysia $2.4 Mn
  31. Singapore $2.1 Mn
  32. Thailand $1.7 Mn
  33. Kenya $1.2 Mn

Report snapshot

India Neuromodulation for Depression Market Analysis at a glance
Market size, 2025$30.1 Mn placeholder estimate
Forecast, 2034$91.0 Mn placeholder estimate
Growth (CAGR), 2025–203413.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersNeuronetics, BrainsWay, Magstim, LivaNova PLC, Flow Neuroscience (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
Active clinical trials1 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

Bar chart: India Neuromodulation for Depression market size, 2024–2034, placeholder estimates. $26.6 Mn in 2024, $30.1 Mn in 2025 and $91.0 Mn in 2034, 13.1% CAGR.
India Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in India

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in India

Neuromodulation for Depression in India: rules, payment and research

Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] ClinicalTrials.gov lists 1 study on Neuromodulation for Depression that is recruiting, active or about to start in India.⁠[3] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for India.⁠[4]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Clinical trials

1 active trial in India

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Magnetic Tides 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 74 papers since 2021 (worldwide)

  1. Subgenual Cingulate Functional Connectivity Predicts Neuromodulation Response in Depression: A Systematic Review. Biological psychiatry global open science, 2026
  2. Neuromodulation Therapies for Depression: Current Status and Future Directions. Alpha psychiatry, 2026
  3. Depressive phenotype shapes behavioral, neuroendocrine and molecular responses to repetitive transcranial magnetic stimulation in preclinical models of depression. Frontiers in molecular neuroscience, 2026
  4. Underuse of neuromodulation in depression care - Authors' reply. Lancet (London, England), 2026
  5. Underuse of neuromodulation in depression care. Lancet (London, England), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

India compared

  • Suicide rate: 14.0 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuromodulation for Depression market in India?
Placeholder estimate: about $30.1 Mn in 2025, rising to about $91.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in India growing?
Placeholder estimate: about 13.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
Who regulates Neuromodulation for Depression in India?
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How many clinical trials on Neuromodulation for Depression are running in India?
1 study is recruiting, active or about to start in India, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
What does WHO report for India?
Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in India are 65 or older?
7.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Neuromodulation for Depression in India? Our analysts can size it for your plan. Talk to us See the public data Suicide rate for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Back to Catalogue
Keep exploring

Related Medical Devices reports in India

See all
Same topic, other categories

Related on mental health and brain and nerves

See the topic